Bloom CEO Christopher Reyes, PhD Patriciates on IamBIO podcast Focused on Exploring the Science of the Microbiome

SAN DIEGO, Calif., March 12, 2024 —The gut microbiome plays a crucial role in our health. However, there is still much to learn about this complex ecosystem. In today’s IamBIO episode, Bloom’s CEO Chris Reyes joins other experts who tell us where the science is—how much we know, and how much we don’t.

About Bloom Science

Bloom Science is a clinical-stage company, trailblazing a path to transformative, novel therapeutics for patients with rare and complex neurological and metabolic disorders. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. The IrisRx™ platform unlocks the potential for developing multi-functional therapeutics from the most common cell type in the human body, gut commensal microbes, while also utilizing an expanding proprietary knowledge base to advance therapeutic candidates based on synthetic biology. Bloom Science is advancing a deep pipeline of programs, including Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and neurodegenerative and cardiometabolic disorders.